Mr. Southwell also held senior executive roles as CFO at Human Genome Sciences through its acquisition by GlaxoSmithKline, and at Sepracor Inc., where he served as Executive Vice President and CFO ...

Beghou Consulting, a leading provider of data, analytics, and technology solutions for life sciences commercialization, today announced that highly-regarded industry leaders Robert Rouse and Jason ...

Background: The proliferation of inhaler devices has resulted in a confusing number of choices for clinicians who are selecting a delivery device for aerosol therapy. There are advantages and ...

- VIM0423, a potential first-in-class oral medicine for isolated dystonia, is currently being studied in a Phase 1 clinical trial; Phase 2 planned for fourth quarter of 2025 CAMBRIDGE, Mass., May 29, ...

The Annals of Pharmacotherapy. 2009;43(3):519-527.